Syndecan-1 levels predict septic shock in critically ill patients with COVID-19.

Abstract

The clinical picture of coronavirus disease 2019 (COVID-19)-associated sepsis is similar to that of sepsis of other aetiologies. The present study aims to analyse the role of syndecan-1 (SDC-1) as a potential predictor of septic shock in critically ill patients with COVID-19. This is a prospective study of 86 critically ill patients due to COVID-19 infection. Patients were followed until day 28 of hospitalization. Vascular biomarkers, such as vascular cell adhesion protein-1, SDC-1, angiopoietin-1 and angiopoietin-2, were quantified upon admission and associated with the need for vasopressors in the first 7d of hospitalization. A total of 86 patients with COVID-19 (mean age 60±16y; 51 men [59%]) were evaluated. Thirty-six (42%) patients died during hospitalization and 50 (58%) survived. The group receiving vasopressors had higher levels of D-dimer (2.46ng/ml [interquartile range {IQR} 0.6-6.1] vs 1.01ng/ml [IQR 0.62-2.6], p=0.019) and lactate dehydrogenase (929±382U/l vs 766±312U/l, p=0.048). The frequency of deaths during hospitalization was higher in the group that received vasoactive amines in the first 24h in the intensive care unit (70% vs 30%, p=0.002). SDC-1 levels were independently associated with the need for vasoactive amines, and admission values >269ng/ml (95% CI 0.524 to 0.758, p=0.024) were able to predict the need for vasopressors during the 7d following admission. Syndecan-1 levels predict septic shock in critically ill patients with COVID-19.